The CHDI Foundation, Inc. (CHDI), a privately-funded research organization, has extended its collaboration with Evotec AG through 2015. Evotec will provide medicinal chemistry, in vitro and in vivo pharmacology, and compound management. The contract has a potential value of $41 million in research payments for Evotec. “We are delighted that CHDI, an organization dedicated solely to the quest to discover novel drugs against Huntington’s disease, continues to work in partnership with ...